USNA — USANA Health Sciences Share Price
- $731.99m
- $399.57m
- $921.01m
- 99
- 87
- 21
- 78
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 14.49 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | -2.82% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.43 | ||
Price to Tang. Book | 1.57 | ||
Price to Free Cashflow | 12.35 | ||
Price to Sales | 0.84 | ||
EV to EBITDA | 4.1 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 15.99% | ||
Return on Equity | 11.39% | ||
Operating Margin | 9.64% |
Financial Summary
Year End 30th Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 1,060.9 | 1,134.64 | 1,186.46 | 998.6 | 921.01 | 862.31 | 878.74 | -4.98% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -13.99 | +33.12 | -2.35 | -37.29 | -8.19 | -24.33 | +8.82 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
USANA Health Sciences, Inc. is a global direct-selling, personal health and wellness company that develops and manufactures science-based nutritional and personal care products. The Company operates through one segment: Direct-selling. Its two geographic regions include Asia Pacific, and Americas and Europe. The Company’s product lines include USANA Nutritionals Optimizers, Essentials/CellSentials, foods, personal care, skin care, and all others. The USANA Nutritionals Optimizers consist of supplements designed to meet individual health and nutritional needs. The Essentials/CellSentials product line includes vitamin and mineral supplements that provide total body nutrition. Its food product line includes meal replacement shakes, snack bars, and other related products. It also offers products designed for prenatal, infant, and young-child age groups in China. It distributes products internationally through direct selling, which entails person-to-person marketing and selling of products.
Directors
- Kevin Guest CHM (58)
- Jim Brown PRE (52)
- G Hekking CFO (51)
- Walter Noot COO (55)
- Paul Jones CHO (57)
- Daniel Macuga CMO (51)
- Robert Sinnott CSO (57)
- P. Joshua Foukas GCN (45)
- Brent Neidig MDR (37)
- David Mulham OTH (60)
- Gilbert Fuller LED (80)
- Robert Anciaux DRC (75)
- Xia Ding IND
- John Fleming IND (76)
- Peggie Pelosi IND (66)
- Frederic Winssinger IND (53)
- Timothy Wood IND (73)
- Last Annual
- December 30th, 2023
- Last Interim
- June 29th, 2024
- Incorporated
- July 20th, 1992
- Public Since
- October 28th, 1993
- No. of Shareholders
- 237
- No. of Employees
- 1,800
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
- New York Stock Exchange
- Shares in Issue
- 19,052,276
- Address
- 3838 W Parkway Blvd, SALT LAKE CITY, 84120-6336
- Web
- https://www.usana.com/
- Phone
- +1 8019547100
- Auditors
- KPMG LLP
Upcoming Events for USNA
Q4 2024 USANA Health Sciences Inc Earnings Release
Similar to USNA
Adecoagro SA
New York Stock Exchange
Altria
New York Stock Exchange
Archer-Daniels-Midland Co
New York Stock Exchange
B&G Foods
New York Stock Exchange
Bellring Brands
New York Stock Exchange
FAQ
As of Today at 24:23 UTC, shares in USANA Health Sciences are trading at $38.42. This share price information is delayed by 15 minutes.
Shares in USANA Health Sciences last closed at $38.42 and the price had moved by -36.73% over the past 365 days. In terms of relative price strength the USANA Health Sciences share price has underperformed the S&P500 Index by -49.95% over the past year.
The overall consensus recommendation for USANA Health Sciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreUSANA Health Sciences does not currently pay a dividend.
USANA Health Sciences does not currently pay a dividend.
USANA Health Sciences does not currently pay a dividend.
To buy shares in USANA Health Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $38.42, shares in USANA Health Sciences had a market capitalisation of $731.99m.
Here are the trading details for USANA Health Sciences:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: USNA
Based on an overall assessment of its quality, value and momentum USANA Health Sciences is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in USANA Health Sciences is $48.00. That is 24.93% above the last closing price of $38.42.
Analysts covering USANA Health Sciences currently have a consensus Earnings Per Share (EPS) forecast of $2.50 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like USANA Health Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -29.82%.
As of the last closing price of $38.42, shares in USANA Health Sciences were trading -16.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The USANA Health Sciences PE ratio based on its reported earnings over the past 12 months is 14.49. The shares last closed at $38.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
USANA Health Sciences' management team is headed by:
- Kevin Guest - CHM
- Jim Brown - PRE
- G Hekking - CFO
- Walter Noot - COO
- Paul Jones - CHO
- Daniel Macuga - CMO
- Robert Sinnott - CSO
- P. Joshua Foukas - GCN
- Brent Neidig - MDR
- David Mulham - OTH
- Gilbert Fuller - LED
- Robert Anciaux - DRC
- Xia Ding - IND
- John Fleming - IND
- Peggie Pelosi - IND
- Frederic Winssinger - IND
- Timothy Wood - IND